Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Bellaire, Texas Clinical Trials

A listing of Bellaire, Texas clinical trials actively recruiting patient volunteers.

RESULTS

Found (26) clinical trials

A Trial of Linaclotide 290 g in Patients With Irritable Bowel Syndrome With Constipation

12 week treatment period followed by 4-week Randomized Withdrawal (RW) Period.

Phase

1.6 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Immunogenicity of V114 Followed by PNEUMOVAX 23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

This study is designed 1) to evaluate the safety, tolerability, and immunogenicity of V114 and Prevnar 13 in healthy adults 50 years of age or older, 2) to describe the safety of sequential administration of V114 or Prevnar 13 followed by PNEUMOVAX23, and 3) to evaluate the immune responses to ...

Phase

1.6 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Immunogenicity of V114 Followed by PNEUMOVAX 23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018/PNEU-WAY)

This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13 in pneumococcal vaccine-nave adults infected with HIV and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX23 when administered 8 weeks after receipt of either V114 or Prevnar 13.

Phase

3.47 miles

Learn More »

Lung-MAP S1400K: c-MET Positive

S1400K of Lung-MAP seeks to evaluate the overall response rate with ABBV-399 (Process II) in patients with c-MET positive SCCA. S1400K is a biomarker-driven study for patients with Stage IV or recurrent squamous cell lung cancer, who have c-MET positive squamous cell tumors.

Phase

3.47 miles

Learn More »

A Study of JNJ-63723283 a Programmed Cell Death Receptor-1 (PD-1) Inhibitor Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

This study is of participants with mCRPC who have progressed after therapy with an androgen receptor (AR)-targeted agent and have not received chemotherapy. Participants must have confirmed prostate-specific antigen (PSA) progression per Prostate Cancer Clinical Trials Working Group (PCWG3) criteria. The primary hypothesis is that treatment with JNJ-63723283 and apalutamide ...

Phase

3.47 miles

Learn More »

Study of Topical SOR007 Ointment for Cutaneous Metastases

This is a Phase 1/2, open-label, dose-rising study evaluating the safety, tolerability and preliminary efficacy of three concentrations of SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment (0.15%, 1.0%, and 2.0%) applied to non-melanoma cutaneous metastases. A treatment area of 50 cm2 will be selected by the Investigator. Using a gloved hand, subjects ...

Phase

3.47 miles

Learn More »

Dual-Time Point (DTP) FDG PET CT for the Post-Treatment Assessment of Head and Neck Tumors Following Definitive Chemoradiation Therapy

The goal of this clinical research study is to compare the results of a dual time point (standard and delayed) FDG PET/CT of the head and neck before and after chemo-radiation therapy. This is an investigational study. The FDG PET/CT is delivered using FDA approved and commercially available methods. It ...

Phase N/A

3.47 miles

Learn More »

Ponatinib + Venetoclax for Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

There are 2 phases to this clinical research study: Phase 1 and Phase 2. The goal of Phase 1 is to find the highest tolerable dose of venetoclax that can be given in combination with ponatinib to patients with certain types of leukemia. The goal of Phase 2 is to ...

Phase

3.47 miles

Learn More »

Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement

Study eyes will be assigned randomly (1:1 ratio) to one of the following 2 treatment arms. Randomization of PDR subjects will be limited to 50% of each arm. Group 1- Subjects will be seen every month, 28 days (+ 7 days), for 52 weeks. All subjects will receive IAI at ...

Phase

3.47 miles

Learn More »

Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have received at least one dose of algenpantucel-L.

Phase N/A

3.47 miles

Learn More »